ALS patient Brian Wallach and his wife, Sandra Abrevaya, have made a significant and positive impact on the ALS community via their heart-wrenching 2022 documentary, “For Love & Life: No Ordinary Campaign.” In case you haven’t seen it yet, I won’t share much about the content. Suffice…
Biotechnology company ProJenX has received a $1 million grant from the ALS Association to support a portion of an ongoing clinical trial, which will test prosetin in people with amyotrophic lateral sclerosis (ALS). The PRO-101 Phase 1 trial (NCT05279755) is testing prosetin in three parts. The…
Since my husband, Todd, was diagnosed with ALS 14 years ago, I’ve been on the lookout for technology that will improve his comfort and quality of life while making my role as his caregiver safer and easier. Moving Todd is hard on me physically. He’s a big guy, and…
Amyotrophic lateral sclerosis (ALS) patients who used NeuroSense Therapeutics‘ investigational therapy PrimeC for a year saw significantly slower disease progression and prolonged survival relative to patients who started the treatment six months later. That’s according to one-year findings from the PARADIGM Phase 2b clinical trial (NCT05357950),…
I like collecting buzzwords. These are the popular words or phrases that weave their way into and out of our language every year. In fact, I think writing this weekly column for the past seven years has sharpened my sensitivity to trendy jargon. Some are fun to use and…
An advisory committee of the European Medicines Agency (EMA) has recommended against granting conditional marketing authorization to masitinib as an oral add-on treatment for amyotrophic lateral sclerosis (ALS). The negative opinion by the Committee for Medicinal Products for Human Use (CHMP) confirms the committee’s view, announced last…
This content is sponsored by Mitsubishi Tanabe Pharma America, Inc. (MTPA) and is intended for US audiences only. Any other present or future content posted by the contributor, not expressly designated as “Mitsubishi Tanabe Pharma America, Inc. – sponsored content” is not associated with MTPA. Craig is an actual patient…
BrainStorm Cell Therapeutics has reached an alignment with the U.S. Food and Drug Administration (FDA) on the chemistry, manufacturing, and controls aspects — known as CMC — of the company’s upcoming Phase 3b trial of NurOwn (debamestrocel), to be tested in people with amyotrophic lateral sclerosis (ALS). This…
In amyotrophic lateral sclerosis (ALS), nerve cells in the spinal cord responsible for inhibiting motor neurons are lost in the early stages of the disease, before the motor neurons themselves, according to a new study done in a genetic mouse model of ALS. The researchers also found that excitatory…
“Plan for what is difficult while it is easy, do what is great while it is small.” — Sun Tzu, “The Art of War” In an earlier column, I noted that there was no handbook to show me how to deal with ALS. Looking back, I admit that…
Get regular updates to your inbox.
